Literature DB >> 2478635

The use of maleimidocaproyloxysuccinimide to prepare malarial peptide carrier immunogens. Immunogenicity of the linking region.

G L Jones1, H M Edmundson, L Spencer, J Gale, A Saul.   

Abstract

Malarial peptides synthesized with an added N terminal cysteine were conjugated to purified diphtheria toxoid (DT) protein using the bifunctional reagent maleimidocaproyloxysuccinimide (MCS). The molar ratio of peptide to carrier was determined by subtractive sulphydryl titration and confirmed by sodium dodecyl sulphate (SDS) electrophoresis. For enzyme-linked immunoabsorbent (ELISA) analysis of sera from animals immunized with the DT conjugates, peptides were conjugated to bovine serum albumin (BSA) using MCS as well as a glutaraldehyde based coupling procedure. Western blotting analysis shows that both DT and BSA adducts were recognized by monoclonal antibodies (Mabs) directed against the peptide epitopes in the native sequences. Animals immunized with the DT-peptide conjugates produced antibodies to the coupling reagent (MCS) as well as diphtheria toxoid and peptide specific antibodies. This MCS specificity could be largely abolished by pre-incubation of sera with a soluble MCS homologue, a thiosuccinimidocaproylamide (TSC).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478635     DOI: 10.1016/0022-1759(89)90224-x

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  3 in total

1.  Determination of protein concentration for protein-protein conjugates using ultraviolet absorption.

Authors:  Daming Zhu; Feng Qian; Yimin Wu; David S Jones; Christopher Rowe; David L Narum; Patrick Duffy; Louis H Miller; Allan Saul
Journal:  J Immunol Methods       Date:  2012-10-23       Impact factor: 2.303

2.  Generation of a Peptide Vaccine Candidate against Falciparum Placental Malaria Based on a Discontinuous Epitope.

Authors:  Catherine J Mitran; Lauren M Higa; Michael F Good; Stephanie K Yanow
Journal:  Vaccines (Basel)       Date:  2020-07-18

3.  Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial.

Authors:  Silvana Sekuloski; Michael R Batzloff; Paul Griffin; William Parsonage; Suzanne Elliott; Jon Hartas; Peter O'Rourke; Louise Marquart; Manisha Pandey; Fran A Rubin; Jonathan Carapetis; James McCarthy; Michael F Good
Journal:  PLoS One       Date:  2018-07-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.